RxDoctor Payments Data

Jodie Sartin, NP

Family · Brookhaven, MSNPI 1699339200

Payments from drug & device makers

$1,298in general payments, 2019–2025

Across 62 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$150
  • Sanofi-aventis U.S. LLC$138
  • Esperion Therapeutics, Inc.$123
  • Boehringer Ingelheim$119
  • AbbVie$115
  • Lilly USA, LLC$114
  • plus $539 from 14 others

What the payments were for

  • Food & beverage$1,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,298 in reported general payments places this provider in the 70th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$116,569
Medicare patients
304
Services billed
2,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin88$74,464
MounjaroTirzepatide59$59,766
EliquisApixaban65$42,485
OzempicSemaglutide23$24,313
FarxigaDapagliflozin Propanediol30$23,292
LinzessLinaclotide23$20,308
XareltoRivaroxaban30$14,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,918
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,348
JanumetSitagliptin Phos/Metformin Hcl12$4,948
Gabapentin175$3,988
Duloxetine Hcl91$2,189
Albuterol Sulfate HfaAlbuterol Sulfate56$1,434
Pantoprazole Sodium126$1,331
Rosuvastatin Calcium92$1,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$119$74,46488 claims
Lilly USA, LLCMounjaro$114$59,76659 claims
PfizerEliquis$30$42,48565 claims
Novo NordiskOzempic$78$24,31323 claims
AstraZenecaFarxiga$114$23,29230 claims
AbbVieLinzess, Synthroid$115$21,05537 claims
MerckJanumet$14$4,94812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,007 family providers in Mississippi.

Other family in Brookhaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →